Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

TCT 2020 | Our Next Goal Should Be Using IVUS Guidance in Every Angioplasty

The benefits of intravascular ultrasound (IVUS) guidance in all angioplasties with second-generation drug-eluting stents (DES) persist through 3 years of follow-up. These data derive from the extended follow-up of the ULTIMATE study, presented virtually at TCT 2020 and published simultaneously in JACC Intv.

TCT 2020 | Guiar con IVUS todas las angioplastias debería ser nuestro próximo objetivo

At 3 years, target-vessel failure remained lower in patients whose angioplasty was guided by IVUS versus unguided angiography (6.6% vs. 10.7%; p = 0.01). This difference was mainly driven by a significant reduction in clinically-driven revascularization (4.5% vs. 6.9%; p = 0.05).

The advantage provided by IVUS guidance was even better when criteria for an optimal procedural result were met (plaque volume <50%, successful expansion, and lack of dissections).

Both the ULTIMATE and the IVUS-XPL (presented at TCT 2019 and also published in JACC Intv.) studies confirm the clinical benefits of IVUS-guided DES angioplasty.


Read also: TCT 2020 | TAVR Appears to Be the Solution for All Dysfunctional Biological Valves.


The ULTIMATE study, conducted at 8 Chinese sites, enrolled 1448 patients who had silent ischemia, stable or unstable angina, or acute infarction (the latter with over 24 hours between index chest pain and procedure). Of all patients, 78.5% presented acute coronary syndrome, 54.9% presented multivessel lesion, and 30.6% had diabetes. Patients in the IVUS arm received, on average, larger-diameter stents and much more frequently post-dilation with non-compliant balloons of larger diameter and at higher atmospheres.

Criteria for an optimal result were: minimum lumen area of the stent segment >5.0 mm2 or 90% of the minimum lumen area at the distal reference segments; plaque burden at 5 mm proximal or distal to stent edge <50%, and no edge dissection involving media with a length >3 mm.

The safety endpoint was definite or probable stent thrombosis, which was observed in 1 patient in the IVUS arm vs. 8 patients in the angiography arm (0.1% vs. 1.1%; p = 0.02).


Read also: TCT 2020 | Initial Studies Show Incredible Results with Lithotripsy in Calcified Lesions.


This research shows that IVUS guidance can improve angioplasty, reducing the need for repeat revascularization and stent thrombosis events.

Original title: Three-Year Outcomes of the ULTIMATE Trial Comparing Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation.

Reference: Xiao-Fei Gao et al. JACC: Cardiovascular Interventions, article in press. DOI: 10.1016/j.jcin.2020.10.001 y presentado simultáneamente en el congreso TCT 2020 virtual.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...